Some new disease-modifying therapies target α-Syn and its pathways, while others target genes and proteins involved in the pathogenesis of PD, including leucine-rich repeat kinase 2 (LRRK2), parkin and glucocerebrosidase. Here, LRRK2 is linked to Parkinson disease.